Comparative Pharmacology
Head-to-head clinical analysis: MERILOG SOLOSTAR versus NOVOLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERILOG SOLOSTAR versus NOVOLIN N.
MERILOG SOLOSTAR vs NOVOLIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
0.5 mg subcutaneously once a day.
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
None Documented
None Documented
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Category C
Category C
Insulin
Insulin